Enzymatic creatinine assays are routinely used in clinical laboratories to provide more accurate estimated glomerular filtration rates and to avoid a perceived lack of analytical specificity associated with picrate (Jaffe) methods. Negative interferences with the enzymatic creatinine assay, which we noted in several patients on dopamine or dobutamine, prompted our further investigation into interference of catecholamines with enzymatic methods.
BACKGROUND:
Enzymatic creatinine assays are routinely used in clinical laboratories to provide more accurate estimated glomerular filtration rates and to avoid a perceived lack of analytical specificity associated with picrate (Jaffe) methods. Negative interferences with the enzymatic creatinine assay, which we noted in several patients on dopamine or dobutamine, prompted our further investigation into interference of catecholamines with enzymatic methods.
METHODS:
Spiked solutions of dopamine, dobutamine, epinephrine, and norepinephrine were added to pooled sera at catecholamine concentrations consistent with clinically relevant dosing. Creatinine was measured enzymatically on the Roche P-Modular, Ortho Clinical Diagnostics Vitros 350, and Abbott i-STAT. Jaffe methods were performed on the Roche P-Modular and Siemens Dimension RxL. In 10 patients receiving dopamine and/or dobutamine via a venous or arterial line we evaluated and compared the extent of in vivo creatinine interference in paired serum samples obtained by venipuncture and from indwelling catheters.
RESULTS:
All catecholamines caused significant negative interference with the Roche enzymatic creatinine assay, most pronounced for dopamine and dobutamine. The Vitros enzymatic assay demonstrated slight negative interferences, and i-STAT enzymatic and Jaffe methods were unaffected by the presence of catecholamines. Significant (P Ͻ 0.001) differences in creatinine concentrations by Roche enzymatic vs Jaffe methods were observed in venipuncture specimens compared with arterial or venous catheter specimens, suggesting dopamine and dobutamine reversibly adhere to the catheter lumen.
CONCLUSIONS:
Negative interferences were pronounced for Roche enzymatic results in blood samples obtained from indwelling catheters, a phenomenon not observed in peripheral draws. Physicians and laboratorians should be alert to the possibility of a falsely low creatinine result and reevaluate questionable samples using a method unaffected by catecholamines.
Accurate measurements of creatinine are critical for identification of patients with chronic and acute kidney disease. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative, the National Kidney Disease Education Program, and the IFCC have advocated use of methods calibrated with isotope-dilution mass spectrometry for measuring serum creatinine (1 ) and calculating estimated glomerular filtration rate (2) (3) (4) . Jaffe methods are subject to chromogenic interferences from glucose, ketones, acetoacetate, cephalosporins, and other reducing substances (5) (6) (7) . Despite modifications to compensate for these interferents, considerable underestimation of estimated glomerular filtration rate was observed with the use of the Modification of Diet in Renal Disease study equation in individuals with a serum creatinine Ͻ155 mol/L (1.75 mg/dL) (8 ) . Enzymatic creatinine methods also have documented interferences. Both dopamine and dobutamine have been reported to cause falsely decreased creatinine, presumably owing to interference with the peroxidase reaction (9 -12 ) .
We observed several hospitalized patients at the Mayo Clinic (n ϭ 6) in whom catecholamine interference with the Roche enzymatic creatinine assay led to clinical confusion, resulting in reevaluation of best practices for creatinine measurement in critically ill patients. The first patient was a 36-year-old man with severe heart failure and increasing renal dysfunction. The patient had a central venous catheter from which all blood samples were drawn. The initial serum creatinine was 407 mol/L (4.6 mg/ dL), with concentrations of 389 mol/L (4.4 mg/dL) and 380 mol/L (4.3 mg/dL) on the following 2 days, prompting admission to the coronary care unit (CCU), where the patient was given dopamine to help improve renal perfusion and urine output. On multiple occasions during the next 2 days, the patient's creatinine unexpectedly decreased Ͼ25%, only to return to previous values with the next sample. These fluctuating creatinine values appeared inconsistent with the patient's unchanged clinical status. Fresh samples were evaluated with enzymatic and Jaffe assays, unmasking spurious reductions with the Roche enzymatic method. During the next week, similar scenarios occurred in 5 other CCU patients, with discrepant results noted between serum enzymatic and Jaffe methods. When creatinine was reanalyzed in stored samples with the Roche enzymatic method, samples more than 24-h-old had concentrations that increased by 44 -88 mol/L (0.5-1.0 mg/dL). The presence of the negative interference in enzymatic creatinine assays was confirmed at another institution (Washington University, St. Louis, MO), and this phenomenon was investigated.
This study was approved by the Mayo Clinic Institutional Review Board. Catecholamine solutions were prepared by the pharmacy at the Mayo Clinic and Barnes-Jewish Hospital. Separate stock solutions contained 800 mg/L dopamine, 1.25 g/L dobutamine, 16 mg/L epinephrine, and 16 mg/L norepinephrine in 0.15 mol/L NaCl. Dopamine, dobutamine, epinephrine, or norepinephrine were added to serum pools with final concentrations of 4 -320 mg/L for dopamine and dobutamine and 0.2-2.0 mg/L for epinephrine and norepinephrine, to approximate concentrations commonly seen with intravenous administration and potentially present in indwelling catheters.
At the Mayo Clinic, creatinine concentrations were determined on a Roche P-Modular analyzer (Roche Diagnostics) using the Creatinine Plus enzymatic and Jaffe reagents. Cholesterol and uric acid, which also use peroxidase to generate a chromogen, were measured on the P-Modular. Enzymatic creatinine was measured on the Vitros 350 (Ortho Clinical Diagnostics). At Washington University/BarnesJewish Hospital, the same Roche enzymatic Creatinine Plus method was compared to the point-of-care i-STAT (Abbott) enzymatic and the Dimension RxL (Siemens) Jaffe methods. The i-STAT enzymatic method determines creatinine by amperometrically measuring the liberation of hydrogen peroxide. All methods were performed in accordance with manufacturers' instructions.
Dopamine and dobutamine caused a large negative interference with the Modular enzymatic creatinine, as well as negative interferences in other tests that use peroxidase to generate signal (Fig. 1A, 1B) . At a 0.25 molar ratio of dopamine (moles of dopamine per moles of creatinine ratio, 0.25:1), the Modular enzymatic assay produced Ϫ67% interference, whereas the Vitros enzymatic, i-STAT enzymatic, RxL Jaffe, and Modular Jaffe methods demonstrated Ϫ13%, Ϫ6%, Ϫ2%, and Ϫ2% interference, respectively. A dopamine-to-creatinine molar ratio as small as 0.05:1 produced Ϫ13% interference in the Modular enzymatic assay. Dobutamine, at a molar ratio of 0.25:1, manifested Ϫ24%, Ϫ7%, Ϫ5%, Ϫ3%, and Ϫ3% interference with the Modular enzymatic, Vitros enzymatic, Serum pools were spiked with (A), dopamine; (B), dobutamine; (C), epinephrine; and (D), norepinephrine. Pools were prepared so that the maximum amount of saline was Ͻ1% of the total sample volume.
i-STAT enzymatic, RxL Jaffe, and Modular Jaffe methods, respectively. The negative interference of dobutamine with the Modular enzymatic method was apparent at a 0.1:1 molar ratio. Other peroxidase-based assays exhibited negative interference to varying degrees (Fig. 1) . Norepinephrine and epinephrine produced negative interferences at even lower molar ratios. At norepinephrine/epinephrine molar ratios of 0.02:1 there was Ͼ25% negative interference in all peroxidase-based chemistry assays examined (Modular and Vitros enzymatic creatinine, uric acid, and cholesterol). Clinically, dopamine produced the largest negative interference, with higher creatinine concentrations manifesting the greatest absolute concentration changes (see the Data Supplement that accompanies the online version of this Brief Communication at http://www.clinchem. org/content/vol55/issue9).
Disappearance of the negative interference in samples stored Ͼ24 h prompted stability studies of the interfering substance(s) in serum pools. Stored samples are often used to investigate questionable results, and an unstable interferent(s) may cause misclassification of these events as random error rather than an analytical interference. Serum pools spiked with catecholamines were analyzed for creatinine at multiple timepoints (see online Data Supplement). In the Modular and Vitros enzymatic and Modular Jaffe methods, the apparent creatinine concentrations of serum pools containing dopamine or dobutamine increased over time, and after 48 h the creatinine was within 10% of the initial pool concentration. The same effect was observed with dobutamine in the Modular cholesterol and uric acid methods, which are also peroxidasecoupled reactions. Reversal of the catecholamine interference over time further obfuscates detection unless clinicians contact the laboratory promptly when results do not match the clinical picture.
To evaluate the clinical implications of the catecholamine interference in the Modular and Vitros enzymatic creatinine assays, sera were obtained from 10 patients with a venous or arterial line receiving dopamine and/or dobutamine via the line. Paired samples from the venous/ arterial lines and venipuncture were collected. Five additional paired samples were collected from an arterial line and by venipuncture in patients receiving epinephrine or norepinephrine. Standard line draw protocols were followed; catecholamine infusion was halted for 2 min, followed by withdrawal of 5 mL of waste blood before specimens were collected for testing. There were significant differences (P Ͻ 0.001) between the Modular enzymatic and Jaffe creatinine results in samples drawn from venous/arterial lines but not in venipuncture samples, suggesting these compounds reversibly adhere to indwelling catheters, similar to the reversible cyclosporine binding reported previously by Lorenz et al. (Table 1 ) (13 ) . Line draw samples were sufficiently different between methods to affect patient management; Vitros enzymatic results were unaffected. Venipuncture samples never showed interference, and they provided reliable creatinine measurement in patients receiving dopamine or dobutamine. Paired catheter and venipuncture samples from patients receiving epinephrine and norepinephrine showed minimal (Ͻ5%) differences in creatinine values, suggesting that these catecholamines do not adhere to indwelling catheters (data not shown). Furthermore, physiologic concentrations of epinephrine and norepinephrine are lower than those found to interfere with laboratory assays (9 ) .
Previous studies demonstrated interference of dopamine and dobutamine with enzymatic creatinine methods that use 4-aminophenazone (9 ) . Alternatively, Vitros assays demonstrated interference because assay conditions favored direct oxidation of the catecholamine, thus depleting the peroxide necessary for chromogen formation (9 ) . In this study, Ͼ50% negative interference with the Modular enzymatic creatinine occurred at lower molar ratios of dopamine (0.25 mol dopamine:1 mol creatinine) and dobutamine (0.40 mol dobutamine:1 mol creatinine) than observed previously (9 ) , signifying the Modular enzymatic assay may have multiple interference mechanisms. Interestingly, the Vitros peroxidase-based assay appears no longer to be adversely affected at physiological catecholamine concentrations, suggesting assay conditions have been optimized. Interference with the Abbott i-STAT device at a stoichiometrically equivalent molar ratio of dopamine to creatinine of 1:1 implies that interference is likely present in other peroxidase-based methods.
Dopamine and dobutamine interference can easily be overlooked because their concentrations normalize substantially by 24 h, which is typically when repeat measurements are performed. To proactively identify and circumvent this problem at the Mayo Clinic, an information technology solution is implemented within the computerized physician order entry system for inpatients. Each time a hospitalized patient has an electrolyte panel or creatinine ordered, the patient's medications are scanned for catecholamines. If the patient is on any catecholamine the specimen will be routed to the appropriate platform, where the Modular Jaffe creatinine assay is performed. During a 5-month period, we monitored patients on dopamine or dobutamine in the CCU and reviewed more than 445 creatinine results assayed by the Modular enzymatic and Jaffe methods. Of these 445, 5% had a significant difference (Ն44 mol/L or 0.5 mg/dL) between methods, causing revised reports. The problem is likely widespread, because catecholamines are administered throughout many areas of our hospitals in addition to the CCU.
Many clinical laboratories have changed from Jaffe to enzymatic creatinine methods to avoid chromogenic interferences, and this strategy may be beneficial in most situations. However, vigilance in patients receiving dopamine or dobutamine is crucial, and blood draws from catheters should be avoided. If this solution is not feasible, Jaffe or enzymatic methods not prone to interference from catecholamines should be used to circumvent falsely low creatinine concentrations. Close monitoring of this interference by clinicians and laboratorians is essential to avoiding potentially serious errors.
